Market Research Reports
Resources
About
Cart (0)

Biological Therapies for Cancer: Technologies and Global Markets

Report Code: BIO048B

Publish Date: Apr 2010

Publisher: BCC Publishing

Category: Cell Biology

Customize This Report

Single User License: $2500

Member Price: FREE

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

  • The global market for biological therapies for cancer was worth $37.9 billion in 2009, down from $38 billion in 2008. This number is expected to increase at a compound annual growth rate (CAGR) of 7.2% to reach $53.7 billion in 2014.
  • The U.S. market for biological therapies for cancer was worth $17.7 billion in 2009, down from $18.8 billion in 2008. This number is expected to increase at a compound annual growth rate (CAGR) of 6.2% to reach $23.9 billion in 2014.
  • The market for biological therapies for cancer in Europe and the rest of the world was worth $15.6 billion in 2009, down from $17.6 billion in 2008. This number is expected to increase at a compound annual growth rate (CAGR) of 7.8% to reach $22.8 billion in 2014.

INTRODUCTION

STUDY GOALS AND OBJECTIVES
 
This BCC Research report, Biological Therapies for Cancer: Technologies and Global Markets, provides a detailed overview and thorough analysis of the present and future global market for cancer biotherapeutics. This report analyzes in detail the biological cancer markets. This report includes products in this market, and detailed analyses of markets and competitive environments, cancer markets in newly emerging therapeutics, and biosimilars and their impact on the market. The report includes information about significant products, key players, issues and trends, current market status of cancer biotherapeutics, strengths, weaknesses, opportunities and threats facing various cancer biotherapeutics already on the market, major issues involved in the research and development (R&D) of more effective cancer therapeutics, and new cancer therapeutics in development and in clinical trials.
REASONS FOR DOING THE STUDY 
The rise in the number of cancer diagnosis, wider access, and affordability of treatment regimes in developing countries will stimulate growth in the world cancer therapies market. It is the second-leading cause of death in the U.S. and according to the American Cancer Society (ACS), 50% of men and 30% of women will develop some form of cancer in their lifetime. Newer biotherapeutics have emerged in the past few years that have had a significant impact on cancer treatment and health. The market for biological therapies in cancer treatment will nearly double in the next 5 years and reach more than $50 billion in the next 5 to 10 years. The demand for newer and innovative oncology drugs will continue to grow as healthcare systems worldwide emphasize cancer detection and treatment. This report covers the current market status of cancer biotherapeutics, strengths, weaknesses, various cancer biotherapeutics already on the market, major issues involved in the R&D of more effective cancer therapeutics, and new cancer therapeutics in development and in clinical trials
SCOPE OF REPORT 
The proposed report will give an update on Biological Therapies for Cancer: Technologies and Global Markets. It will review global markets for biologic therapeutics for cancer and will forecast trends for use of biologics and cancer treatment through 2014. Important biologics, market share by type of cancer, products on the market and market share by company, statistical information for types of cancers prevalent worldwide, with special emphasis on the U.S. market. The report also includes current issues and trends affecting the industry, costs, and factors influencing demand will be discussed. The report covers, biological products in development, biological products in clinical trials, currently marketed and late-stage development biologic cancer products. 
The market and sales data in 2008 provides once again strong support for the R&D paradigm shift to biologic treatment for cancer and within biologic toward human monoclonal antibodies (mAbs), vaccines, and interferons (IFNs). The following biologic drug classes will be discussed in this report with a special focus on cancer treatment: 
  • mAbs
  • Vaccines
  • Erythropoietin (EPO)
  • Colony stimulating factors (CSFs)
  • Interleukins (ILs) and IFNs
The following approaches to cancer therapeutics are excluded from this report: chemotherapy, alkylating agents, antimetabolites, cytotoxic agents, plant derivatives, and hormone therapy corticosteroids, hormone antagonists/antagonists aromatase inhibitors selective estrogen receptor modulators (SERMs), radiation therapy and adjunctive therapy. Biological therapies for treatment of other diseases will not be addressed in this report.
INTENDED AUDIENCE
 
This report is an exhaustive study on the worldwide biological cancer treatment market, giving crucial statistics and analysis on the prevalence of cancer, market structure, market size, key drug segments, important trends in technology development, major opportunities, and market shares of key players and drugs. This report may prove crucial for the firms or investors seeking investments in the concerned sector. Biological therapy (sometimes called immunotherapy, biotherapy, or biological response modifier [BRM] therapy) is a relatively new addition to the family of cancer treatments that also includes surgery, chemotherapy, and radiation therapy. Biological therapies use the body’s immune system, either directly or indirectly, to fight cancer or to lessen the side effects that may be caused by some cancer treatments.
METHODOLOGY
 
Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to paid databases. The base year of the report is 2008, with forecast data provided through 2014. Historical, base year and forecast data are provided for each market segment of this report. Growth rates are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D, and current product growth, etc. 
ANALYST CREDENTIALS
 
Usha Nagavarapu is an experienced pharmaceutical professional with business development experience. She has more than 10 years of preclinical, alliance management, discovery and technology development marketing experience. Her strong focus areas include oncology and cardiovascular diseases, with expertise in molecular and cell biology and complex cell-based biological assays ranging from drug discovery, in-vitro and in-vivo screening, in-vivo model development, and pharmacokinetics. She has experience working with early start-ups.
BCC ONLINE SERVICES
 
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
  • Examine BCC’s complete catalog of Market Research Reports and place direct orders
  • Subscribe to any of BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on any BCC product
  • Take advantage of special offers 
 
DISCLAIMER
 
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use. 
Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW
Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
[+] Show Chapter Details
Title/Chapter NamePagesMember Price
Full Report: Biological Therapies for Cancer: Technologies and Global Markets325Free
Chapter- 1: INTRODUCTION4Free
Chapter- 2: SUMMARY3Free
Chapter- 3: OVERVIEW17Free
Chapter- 4: BIOTHERAPEUTICS54Free
Chapter- 5: PRODUCTS IN DEVELOPMENT26Free
Chapter- 6: MARKET DATA21Free
Chapter- 7: GLOBAL CANCER STATISTICS 29Free
Chapter- 8: DESCRIPTION OF CANCERS 89Free
Chapter- 9: COMPANIES/GLOBAL PLAYERS21Free
Chapter- 10: ISSUES AND TRENDS AFFECTING THE BIOLOGIC CANCER MARKET 59Free
Chapter- 11: BIBLIOGRAPHY2Free
Published - Jun-2004| Analyst - Lynn Gray| Code - BIO048A

Report Highlights

  • The current worldwide market for therapeutics from transgenic sources is zero, but is expected to exceed $1 billion in 2008 and reach $18.6 billion in 2013.
  • the projection for 2013.

Related Reports

Recent Reports

Bioprocess Optimization and Digital Bio-manufacturing: Global Markets

Published - Dec 2024 | Publisher - BCC Publishing | Code - BIO170B

The global market for bioprocess optimization and digital biomanufacturing is expected to grow from $24.3 billion in 2024 and is projected to reach $39.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2024 to 2029.

Global DNA Sequencing: Research, Applied and Clinical Markets

Published - Dec 2024 | Publisher - BCC Publishing | Code - BIO045J

The global market for DNA sequencing is expected to grow from $14.8 billion in 2024 and is projected to reach $34.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 18.6% during the forecast period of 2024 to 2029.

Artificial Intelligence (AI) in Cancer

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO196B

The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.

Cell and Gene Therapy Tools, and Reagents: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO208C

The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.

Single-use Technologies for Biopharmaceuticals: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO099F

The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.

Top Trending Reports

Single-use Technologies for Biopharmaceuticals: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO099F

The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.

Cell and Gene Therapy Tools, and Reagents: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO208C

The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.

Medical Devices Industry: Competitive Landscape

Published - Nov 2024 | Publisher - BCC Publishing | Code - MDS010C

The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.

Global Market Opportunities and Competitive Landscape for CDMO

Published - Nov 2024 | Publisher - BCC Publishing | Code - PHM238B

The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.

Chronic Disease Management: Therapeutics, Device Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC239C

The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Biological Therapies for Cancer: Technologies and Global Markets
Customize This Report
Customize Report
Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.
Contact
© 2024 BCC Research
Privacy Policy |Site Map|Terms & Conditions